Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Prestige BioPharma

Request full access

Specializing in the discovery and development of innovative biologics and biosimilars

Singapore, SingaporeFounded 2005Biotech & Life Sciences

About Prestige BioPharma

Prestige BioPharma is a biopharmaceutical company focused on the discovery and development of innovative biologics and biosimilars. The company operates primarily in the APAC region but is rapidly expanding its footprint globally. Prestige BioPharma's core business involves the research and development of new antibody therapeutics and biosimilars, which are essentially generic versions of biologic drugs. These biosimilars are designed to be more affordable and accessible alternatives to existing biologic treatments, addressing unmet medical needs and providing cures for devastating diseases.

The company's flagship product, HD201 Trastuzumab, is currently in global Phase III clinical trials and is expected to launch in the market soon. Prestige BioPharma's business model revolves around leveraging its solid and innovative technology platform to develop a pipeline of biosimilar drugs that are in various stages of clinical and nonclinical development. By doing so, the company aims to become a leading player in the global biopharmaceutical market.

Revenue is generated through the commercialization of these biosimilars and new biologics, targeting healthcare providers, hospitals, and pharmaceutical companies that require cost-effective and high-quality therapeutic solutions.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
93
Open positions
None listed
Dealroom signal
78.4/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
IPO✓Exit Feb 2021 $396M $396M Undisclosed —
ACQUISITION✓Exit Dec 2020 $0 — Korea Securities Depository —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Prestige BioPharma website traffic

Latest recorded traffic for Prestige BioPharma is 3.8K monthly website visits, down 70.8% over the last three months. Prestige BioPharma's team grew 52.5% over the past year.

Latest monthly visits3.8K 3-month web change-70.8% 1-year team growth+52.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Prestige BioPharma in the Singapore ecosystem

Live from Dealroom

The Prestige BioPharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Other known investors2 additional known investors

  • Korea Securities Depository
  • TS investment
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇸🇬 Singapore74.5%
🇰🇷 South Korea23.6%
🇮🇳 India1.8%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Prestige BioPharma on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Prestige BioPharma’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.